跳轉至內容
Merck
全部照片(1)

重要文件

AB3610

Sigma-Aldrich

Anti-Survivin Antibody

serum, Chemicon®

同義詞:

TIAP

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

rabbit

品質等級

抗體表格

serum

抗體產品種類

primary antibodies

無性繁殖

polyclonal

物種活性

human

製造商/商標名

Chemicon®

技術

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

UniProt登錄號

運輸包裝

wet ice

目標翻譯後修改

unmodified

基因資訊

human ... BIRC5(332)

一般說明

Apoptosis is triggered by a variety of stimuli, including members of the Tumor Necrosis Factor (TNF) family, and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. One of these IAP proteins, Survivin/TIAP, interacts with the processed form of caspase-3 and has been shown to inhibit its proteolytic activity. Survivin/TIAP is predominantly expressed in tissues of embryos, transformed cell lines, and many human cancers and lymphomas.

免疫原

Recombinant, GST-tagged full length human Survivin

應用

Immunoblotting: Recommended antibody dilution 1:3000-6000

Immunoprecipitation: Recommended antibody dilution 1:200

Immunohistochemisty: Recommended antibody dilution 1:1500

Optimal antibody dilutions must be determined by end-user.
This Anti-Survivin Antibody is validated for use in WB, IP, IH for the detection of Survivin.

外觀

Serum with no preservatives

儲存和穩定性

Maintain at -20°C for up to 6 months after date of receipt.

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Wang, H; Cui, XX; Goodin, S; Ding, N; Van Doren, J; Du, Z; Huang, MT; Liu, Y; Cheng et al.
Oncology Reports null
Linfei Hu et al.
Cell death & disease, 13(2), 124-124 (2022-02-10)
The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of thyroid cancer (TC), and finding more effective multitarget combination therapies may be an important solution. In the present study, we found strong correlations between Ref-1 high
Oral Free Paper Sessions.
Virchows Archiv : an international journal of pathology, 469 Suppl 1, 1-346 (2016-08-25)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務